GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments

Core Viewpoint - GenSight Biologics is strategically expanding its Regulatory Affairs & Quality department with two senior appointments following recent regulatory milestones [1] Group 1: Company Developments - The company focuses on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders [1] - The recent appointments in the Regulatory Affairs & Quality department are part of the company's efforts to enhance its regulatory capabilities [1]